We will be closed on Thanksgiving, November 26, 2020. We will be open on November 27, 2020.

Research

Synthetic Neoepitopes of the Transglutaminase-Deamidated Gliadin Complex as Biomarkers for Diagnosing and Monitoring Celiac Disease. Choung RS, Khaleghi Rostamkolaei S, Ju JM, Marietta EV, Van Dyke CT, Rajasekaran J, Jayaraman V, Wang T, Bei K, Rajasekaran KE, Krishna K, Krishnamurthy HK, Murray JA. Gastroenterology 2019;156(3):582-591 e1.

Synthetic Neoepitopes of the Transglutaminase-Deamidated Gliadin Complex as Biomarkers for Diagnosing and Monitoring Celiac Disease. Choung RS, Khaleghi Rostamkolaei S, Ju JM, Marietta EV, Van Dyke CT, Rajasekaran J, Jayaraman V, Wang T, Bei K, Rajasekaran KE, Krishna K, Krishnamurthy HK, Murray JA. Gastroenterology 2019;156(3):582-591 e1.

We identified immunogenic epitopes of the tTG-DGP complex, and found that an assay to measure the immune response to epitopes accurately identified patients with Celiac disease, as well as patients with mucosal healing. The assay identified patients with mucosa healing status with 84% sensitivity and 95% specificity. This biomarker assay might be used in detection and monitoring of patients with Celiac disease.

Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease.
Siriwardhane T, Krishna K, Ranganathan, V, Jayaraman V, Wang T, Bei K, Ashman S, Rajasekaran K, Rajasekaran JJ, Krishnamurthy H. Autoimmune Diseases. 2019; Article ID 1684074.

Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease.
Siriwardhane T, Krishna K, Ranganathan, V, Jayaraman V, Wang T, Bei K, Ashman S, Rajasekaran K, Rajasekaran JJ, Krishnamurthy H. Autoimmune Diseases. 2019; Article ID 1684074.

In this study, our motive is to showcase the early appearance of thyroid autoantibody, anti-TPO, prior to the onset of thyroid hormone disruption; hence the addition of anti-TPO in conjunction with traditional thyroid markers TSH and FT4 would aid to reduce the long-term morbidity and associated health concerns. According to our results, 73% of hypothyroid subjects and 68.6% of hyperthyroid subjects had anti-TPO 252 (±33) and 277 (±151) days prior to the onset of the thyroid dysfunction, respectively. Both subclinical/overt hypothyroidism and hyperthyroidism showed a significantly higher percentage of subjects who had anti-TPO prior to the onset of thyroid dysfunction compared to the combined control group.

Human Reproductive Health in Relation to Thyroid Alterations
Siriwardhane T, Krishna K, Devarajan K, Song Q, Ranganathan, V, Jayaraman V, Wang T, Bei K, Rajasekaran JJ, Krishnamurthy H. Health. 2019: 11(8): Article ID 94771.

Human Reproductive Health in Relation to Thyroid Alterations
Siriwardhane T, Krishna K, Devarajan K, Song Q, Ranganathan, V, Jayaraman V, Wang T, Bei K, Rajasekaran JJ, Krishnamurthy H. Health. 2019: 11(8): Article ID 94771.

In this study, we performed a comprehensive analysis on the effects of different thyroid abnormalities on sexual and reproductive-related hormones in both men and women in different age groups. Women with hypothyroidism had elevated cortisol and low SHBG and DHEA-S. Women with hyperthyroidism showed elevated total testosterone and SHBG. Women seropositive for anti-TPO had elevated total testosterone and low cortisol. Women seropositive for anti-Tg had low parathyroid hormones. Similarly, a total of 4417 men was tested. Men with hypothyroidism had low IGF-I. Similarly, men with hyperthyroidism had low DHEA-S, but elevated estradiol, FSH, LH and prolactin. Men seropositive for anti-TPO had elevated SHBG and low progesterone. Men seropositive for anti-Tg had elevated progesterone. The reproductive and related hormone levels of age group 36-49 showed the most variations.

Evaluation of the Vibrant DNA microarray for the high-throughput multiplex detection of enteric pathogens in clinical samples.
Yang Y, Rajendran V, Jayaraman V, Wang T, Bei K, Krishna K, Rajesekaran K, Rajasekaran J. J, Krishnamurthy H. Gut Pathogens. 2019;11: Article ID 51.

Evaluation of the Vibrant DNA microarray for the high-throughput multiplex detection of enteric pathogens in clinical samples.
Yang Y, Rajendran V, Jayaraman V, Wang T, Bei K, Krishna K, Rajesekaran K, Rajasekaran J. J, Krishnamurthy H. Gut Pathogens. 2019;11: Article ID 51.

This study aims at developing and evaluating a DNA microarray-based qualitative multiplexed polymerase chain reaction (PCR) assay, Vibrant GI pathogen panel (GPP), for simultaneous detection of 27 enteric GI pathogenic targets (16 bacteria, 5 viruses, 4 parasites, and 2 fungi) directly from stool specimens. Limits of detection ranged from 102 to 104 cells/mL for bacteria, 102 to 103 cells/mL for parasites, 102 to 103 RNA copies/mL for viruses, and 102 to 103 cells/mL for fungi. Performance characteristics were determined using 27 Quantitative Genomic DNAs, 212 spiked stool specimens, 1067 clinical and archived stool specimens. Overall sensitivity was 95.9% (95% CI 92.4–98.1) and specificity was 100% (95% CI 99.9–100). Polymicrobial detections contained either two or three organisms was 20.2% (35/173) of positive clinical specimens and 3.3% (35/1055) of all clinical specimens.

Overlap of Characteristic Serological Antibodies in Rheumatoid Arthritis and Wheat-Related Disorders

Overlap of Characteristic Serological Antibodies in Rheumatoid Arthritis and Wheat-Related Disorders.” Yang Y, Deshpande P, Krishna K, Ranganathan V, Jayaraman V, Wang T, Bei K, Rajasekaran JJ, Krishnamurthy H. Disease Markers. 2019; Article ID 4089178.

Rheumatoid arthritis (RA) and celiac disease (CD) are members of the autoimmune disease family while they have been shown to share multiple aspects in epidemiology and clinical manifestations. In this study, we observed a significantly greater frequency of RA markers in seropositive subjects with wheat-related disorders as well as wheat protein antibodies in RA subjects compared with the respective seronegative controls.

Insights into Cardiovascular Risk and Nutritional Status in Subjects with Wheat-related Disorders

Insights into Cardiovascular Risk and Nutritional Status in Subjects with Wheat-related Disorders.” Siriwardhane T, Krishna K, Devarajan K, Ranganathan, V, Jayaraman V, Wang T, Bei K, Rajasekaran JJ, Krishnamurthy H. Biomarkers. 2019:1-11.

The objective of the study was to explore the lipid profiles and the nutritional status of subjects with wheat-related disorders to understand the potential threat by wheat on cardiovascular risk and nutritional deficiency. Subjects with both Wheat Zoomer positivity (WZ+) and celiac disease positivity had significantly low levels of high-density lipoproteins (HDL) (279/483(57.8%) and 29/47(61.7%) respectively), but only subjects with WZ + had low levels of apo A1 (44/424(9.5%)), and high levels of Omega 6 fatty acids (53/334(15.9%)). None of the micronutrients tested showed a significant imbalance in WZ + subjects.

High Frequency of Extractable Nuclear Autoantibodies in Wheat-Related Disorders

High Frequency of Extractable Nuclear Autoantibodies in Wheat-Related Disorders.” Yang Y, Krishna K, Deshpande P, Ranganathan V, Jayaraman V, Wang T, Bei K, Krishnamurthy H. Biomarker insights. 2018;13:1177271918782893.

In this study, we evaluated the frequencies and levels of autoantibodies, which are important biomarkers of autoimmunity, in subjects with wheat-related disorders and controls. The detected portion of anti-nuclear antibodies (ANA) in wheat-related disorders was very close to the reported occurrence of ANA positivity (15%) in the healthy population, the prevalence of anti- extractable nuclear antigens (ENA) was reported to be less than 2% in the general population; however, our study found it to be much higher in the celiac disease subjects (29%) and the wheat-sensitive subjects (27%), compared with a smaller proportion of seronegative controls (19%).

A Multiplex Autoantibody Panel for Early Detection of Autoimmune
Disease Activity

A Multiplex Autoantibody Panel for Early Detection of Autoimmune Disease Activity.” Yang Y, Krishna K, Ranganathan V, Jayaraman V, Wang T, Bei K, Krishnamurthy H, Rajasekaran JJ. Open Journal of Rheumatology and Autoimmune Diseases. 2018;8(2):43-52.

In diagnosis of systemic autoimmune disorders, a cascade autoantibody testing is usually performed by employing antinuclear antibodies (ANA) test as a first screening test and extractable nuclear antigen (ENA) tests as second level determinations. In this study, we evaluated the clinical significance of a multiplex ANA + ENA panel. The two-year follow-up study showed that anti-ENA antibodies may exist years earlier than ANA. Combining ENA tests with ANA screening may reduce false negatives and improve sensitivity.

Exploring Systemic Autoimmunity in Thyroid Disease Subjects

Exploring Systemic Autoimmunity in Thyroid Disease Subjects.” Siriwardhane T, Krishna K, Ranganathan, V, Jayaraman V, Wang T, Bei K, Rajasekaran JJ, Krishnamurthy H. Journal of Immunology Research. 2018; Article ID 6895146.

Individuals with one autoimmune disease are at risk of developing a second autoimmune disease. In this study, we evaluated thyroid hormones, thyroid-stimulating hormone (TSH), free thyroxine (FT4), thyroid autoantibodies, anti-thyroperoxidase (anti-TPO), and anti-thyroglobulin (Tg) to comprehend the association with systemic autoimmune autoantibodies, anti-nuclear antibodies (ANA), and autoantibodies to extractable nuclear antigens (ENA) in subjects with thyroid-related symptoms. During the 2-year follow-up study, anti-TPO appeared significantly earlier than ANA and anti-ENA in an average of 253 (±139) and 227 (±127) days, respectively.

Expanding Immune Reactivity Against Gliadin and TTG Epitopes Long Precedes Celiac Disease Diagnosis

Expanding Immune Reactivity Against Gliadin and TTG Epitopes Long Precedes Celiac Disease Diag nosis.” Choung RS, Jayaraman V, Marietta EV, Rajasekaran J, Wang T, Bei K, Krishnamurthy HK, Murray JA. Gastroenterology. 2018;154(6):S-119.

The aim of this study was to explore the changes of immune recognition against gliadin peptides and tissue transglutaminase in serum samples of a young adult population subsequently diagnosed with CD. Surprisingly, even 6 years before diagnosis, immune responses against gliadin peptides are already present in a subset of celiac patients. This immune reactivity was further augmented as disease progressed from silent to clinically obvious disease.

Reactivity to Neoepitopes of DGP-TTG Complexes can Predict the Healing Status in Treated Celiac Patients

Reactivity to Neoepitopes of DGP-TTG Complexes can Predict the Healing Status in Treated Celiac Patients” Choung RS, Khaleghi S, Marietta EV, Van Dyke CT, Rajasekaran J, Jayaraman V, Wang T, Bei K, Krishnamurthy HK, Snyder MR, Murray JA. Gastroenterology. 2017;152(5):S70.

The aim of this paper is to identify if the pattern of antibody recognition to native and deamidated gliadin derived peptides and tTG as well as novel combinations of peptides derived from both are predictive of mucosal healing of celiac disease (CD). We created neo-epitopes that could be found in a complex of deamidated gliadin peptides and tTG. The loss of the immune responses to the neo-epitopes showed a high sensitivity (84%) and specificity (95%) with a positive predictive value of 0.94 and a negative predictive value of 0.86 to identify healing status of CD.

Determination of B-Cell Epitopes in Patients with Celiac Disease: Peptide Microarrays

Determination of B-Cell Epitopes in Patients with Celiac Disease: Peptide Microarrays.” Choung RS, Marietta EV, Van Dyke CT, Brantner TL, Rajasekaran J, Pasricha PJ, Wang T, Bei K, Krishna K, Krishnamurthy HK, Snyder MR, Jayaraman V, Murray JA. PLoS ONE. 2016;11(1):e0147777.

A novel microarray method for identifying discontinuous B-cell epitopes in celiac disease (CD) by using a silicon-based peptide array and computational methods is presented. Overlapping 12-mer peptide sequences of all native and deamidated gliadins, which are known to trigger CD, were synthesized in situ on the microarray platform and used to identify peptide epitopes. By combining the most discriminative 3-mer gliadin sequences with randomly interpolated 3- or 6-mer peptide sequences, novel discontinuous epitopes were identified and were tested in a confirmatory cohort of CD patients and controls, yielding 99% sensitivity and 100% specificity.

Utilizing High Throughput Discovery Approach to Identify Optimal Candidate Deamidated Gliadin Peptides for the Identification of Celiac Disease.

Utilizing High Throughput Discovery Approach to Identify Optimal Candidate Deamidated Gliadin Peptides for the Identification of Celiac Disease.” Murray JA, Snyder M, Van Dyke CT, Brantner TL, Jayaraman V, Bei K, Wang T, Krishnamurthy HK, Rajasekaran JJ. Gastroenterology. 2013;144(5):S-253.

The aim of this paper is to identify sequences of the deamidated gliadin family (alpha, beta, gamma, omega gliadin) that are most predictive of celiac disease using a high-density in situ synthesized peptide microarrays in combinatorial analysis. Result suggests that antibody recognition of epitopes of DG in CeD is highly sequence specific and only a few sequences are recognized across the entire spectrum of patients with CeD. Similar sequences are recognized by IgA and IgG but thus far the IgA isotype is much more sensitive than IgG (90% vs 68%).

Vibrant values research and clinical validity in its laboratory tests above all else. In seeking to develop new tests or improve existing tests, we have collaborated with a number of reputable individuals and organizations to better refine and validate our laboratory products.

Some of our collaborators include:
Joseph A. Murray, M.D., Mayo Clinic (Wheat Zoomer and Celiac)
Edwin H. Kim, M.D., University of North Carolina at Chapel Hill (Peanut Zoomer and Peanut Component)
Daniel A. Green, M.D., Columbia University (Gut Zoomer and Tickborne Disease)

Would you like to collaborate with us? Please fill out the form below and a member of our research and development team will be in touch.









Quality Control

Vibrant America’s mission is dedicated to bringing clinically relevant tests at a rapid pace to enable affordable high-quality diagnostics to every individual.

Yet, more importantly, our organization believes that we need to institute practices which ensure compliance with all applicable laws, rules, and regulations, especially those dealing with healthcare fraud, abuse, and false claims.

Integrity is the foundation of what we do each and every day. Therefore, we have instituted operational measures and monitors into our day-to-day procedures which demonstrate our commitment to operate our business in an ethical and compliant manner.

At Vibrant America, we are committed to the adherence to laws, rules, and regulations governing our business and strictly comply to all our own internal policies and procedures, including HIPAA, OSHA, CAP, state licensing regulations, and others.

We have implemented practices which will safeguard our organization from adverse consequences such as government fines, criminal prosecution, and the loss of our reputation and goodwill.

In order to ensure impeccable practices, Vibrant America has developed a compliance program and HIPAA privacy program that follows the recommendations by U.S. government. By doing so, we believe we have created a culture that fosters undisputed integrity, transparency, and accountability. The Vibrant America Compliance Program is led by Larry Small and Cheri Copie, RN, who both have more than 20 years of experience in healthcare law, regulation, and compliance.

Healthcare laws and regulations that apply to Vibrant America business activities include, but are not limited to:

  • All Vibrant employees must participate in mandatory, ongoing compliance education training.
  • All Vibrant employees comply with all aspects of the Anti-Kickback Statute and Stark Law.
  • All Vibrant employees abide by the Code of Conduct and Ethics, which is designed to assist in complying with applicable state and federal laws and conducting business in an ethical manner.
  • All laboratory employees abide by both Clinical Laboratory Improvement Amendments (CLIA) and The College of American Pathologist (CAP)
  • All laboratory tests are developed using ISO-13485 technology.

CLIA certified: Vibrant America is CLIA certified. This is a basic requirement for all laboratories that wish to test human samples. For more information about CLIA certification, please click here.

CAP accredited: Vibrant America has gone above and beyond the minimum of CLIA certification and attained CAP accreditation.

Vibrant America is the only CAP-accredited laboratory in the functional medicine lab testing industry.

CAP accreditation requires rigorous quality control standards and a high degree of accuracy to be demonstrated multiple times per year on blinded samples.

Because of this, Vibrant is confident in the laboratory test results provided as being valid, sensitive, specific, reproducible, and, most of all, accurate. For more information about CAP accreditation, please click here.